Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2023 | KEYNOTE-921: pembrolizumab plus docetaxel in chemotherapy-naïve mCRPC

Treatment options for men with metastatic castration-resistance prostate cancer (mCRPC) following failure with next-generation hormonal agents (NHAs) are limited and only provide only moderate survival benefit. Pembrolizumab has previously been demonstrated to provide benefit as monotherapy in patients with mCRPC, as well as in combination with docetaxel and prednisone/prednisolone for patients previously treated with enzalutamide or abiraterone acetate. Daniel P. Petrylak, MD, Yale Cancer Center, New Haven, CT, provides an overview of the Phase III KEYNOTE-921 (NCT03834506) trial investigating pembrolizumab plus docetaxel versus docetaxel monotherapy in patient with chemotherapy- naïve mCRPC previously treated with next-generation hormonal agents (NHAs). The coprimary endpoints were overall-survival (OS) and radiographic progression-free survival (rPFS). Secondary endpoints include time to initiation of the first subsequent anti-cancer therapy, prostate-secific antigen (PSA) response rate, objective response rate (ORR) and duration of response (DOR). No difference was found in the rPFS or OS in patients receiving docetaxel alone or with pembrolizumab. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.